Figure 7.

Synergistic effect of RSK inhibition by BI-D1870 and EGFR inhibition by erlotinib. (A) PaTu-8988t cells were treated with BI-D1870 (5 µM) and/or erlotinib (10 µM), and PARP cleavage was determined by Western blot analysis after 24 hours. (B) PaTu-8988t cells stably overexpressing RSK3 or empty vector (Mock) were treated with BI-D1870 and/or erlotinib, and apoptosis was determined by DNA fragmentation assays. *P < .05 compared to either Mock clone. Data are representative for three independent experiments.